Epigenomics Ag (EPGNY) 39.9800 $EPGNY
Epigenomics AG Begins Trading on OTCQX®
PR Newswire - Fri Jan 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Epigenomics AG (OTCQX: EPGNY; Frankfurt Stock Exchange: ECX, Prime Standard), a German-American molecular diagnostics company developing and commercializing products for cancer screening and diagnosis, has chosen to have its American Depositary Receipts (ADRs) trade on OTCQX®, the best marketplace with qualified companies.
2013 Report on the International Biomarkers Market - Includes Forecasts to 2018
M2 - Thu Dec 19, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/jjq7jz/biomarkers_market) has announced the addition of the "2013 Report on the International Biomarkers Market - Includes Forecasts to 2018" report to their offering. Biomarkers comprise definite cells, genes, molecules, gene products, enzymes, or hormones which are objectively measured as an indicator of typical biological processes, pathogenic processes, or pharmacologic response to a therapeutic intrusion. Major application areas of biomarkers are early disease diagnosis and prevention, drug target recognition, and drug discovery and development. The global market showcases high growth potential in the near future. This market is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018. The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.) Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Biomarkers Market, By Discovery Technologies 5 Services Market Of Biomarkers 6 Biomarkers Application Market 7 Biomarkers Indication Market 8 Geographical Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories - BGI - Bayer Ag - Bristol-Myers Squibb - Caprion Proteomics Inc - Crescendo Bioscience - Eisai Co Ltd - Epiontis GMBH - Epistem Holdings PLC - Eurogentec SA - Evotec AG - Glaxosmithkline PLC - Ipsen - Johnson & Johnson - Merck & Co - Micromedic Technologies Ltd - Myriad Genetics Inc - Nextgen Sciences Inc - Novartis International AG - Ocimum Biosolutions Ltd - Pacific Biomarkers Inc - Pfizer Inc - Pronota NV - Proteome Sciences Plc - Qiagen Nv - Quintiles Transnational Corporation - Roche Diagnostics Limited - Sanofi-Aventis - Siemens Healthcare - Trans-Hit Biomarkers Inc - Vermillion Inc For more information visit http://www.researchandmarkets.com/research/jj...ers_market
S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poor's Factual Stock Reports
PR Newswire - Fri Sep 06, 9:55AM CDT
S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Epigenomics AG.
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The World Market For Personalized Medicine: Key Competitors Covered and Forecasts Provided to 2016
M2 - Wed Jul 17, 6:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z6sk/personalized) has announced the addition of the "The World Market For Personalized Medicine" report to their offering. This world market report includes important core medical product areas that will continue to have a powerful impact on current and future healthcare delivery. This business report examines key market segments such as targeted drugs and key personalized medicine diagnostics, including companion diagnostic IVDs, LDTs, diagnostic services and related tools or technologies. Many people already know about DNA, genes and the human genome. The science driving personalized medicine includes pharmacogenetics, pharmacoproteomics and pharmacometabalomix. Personalized medicine uses a targeted drug that depends on the patient information identified by a companion diagnostic (genetic biomarker test). The companion diagnostic identifies which patients would likely benefit from a particular therapy or those who might suffer from a ba
Epigenomics AG Begins Trading on OTCQX®
PR Newswire - Fri Jan 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Epigenomics AG (OTCQX: EPGNY; Frankfurt Stock Exchange: ECX, Prime Standard), a German-American molecular diagnostics company developing and commercializing products for cancer screening and diagnosis, has chosen to have its American Depositary Receipts (ADRs) trade on OTCQX®, the best marketplace with qualified companies.
2013 Report on the International Biomarkers Market - Includes Forecasts to 2018
M2 - Thu Dec 19, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/jjq7jz/biomarkers_market) has announced the addition of the "2013 Report on the International Biomarkers Market - Includes Forecasts to 2018" report to their offering. Biomarkers comprise definite cells, genes, molecules, gene products, enzymes, or hormones which are objectively measured as an indicator of typical biological processes, pathogenic processes, or pharmacologic response to a therapeutic intrusion. Major application areas of biomarkers are early disease diagnosis and prevention, drug target recognition, and drug discovery and development. The global market showcases high growth potential in the near future. This market is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018. The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.) Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Biomarkers Market, By Discovery Technologies 5 Services Market Of Biomarkers 6 Biomarkers Application Market 7 Biomarkers Indication Market 8 Geographical Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories - BGI - Bayer Ag - Bristol-Myers Squibb - Caprion Proteomics Inc - Crescendo Bioscience - Eisai Co Ltd - Epiontis GMBH - Epistem Holdings PLC - Eurogentec SA - Evotec AG - Glaxosmithkline PLC - Ipsen - Johnson & Johnson - Merck & Co - Micromedic Technologies Ltd - Myriad Genetics Inc - Nextgen Sciences Inc - Novartis International AG - Ocimum Biosolutions Ltd - Pacific Biomarkers Inc - Pfizer Inc - Pronota NV - Proteome Sciences Plc - Qiagen Nv - Quintiles Transnational Corporation - Roche Diagnostics Limited - Sanofi-Aventis - Siemens Healthcare - Trans-Hit Biomarkers Inc - Vermillion Inc For more information visit http://www.researchandmarkets.com/research/jj...ers_market
S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poor's Factual Stock Reports
PR Newswire - Fri Sep 06, 9:55AM CDT
S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Epigenomics AG.
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The World Market For Personalized Medicine: Key Competitors Covered and Forecasts Provided to 2016
M2 - Wed Jul 17, 6:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z6sk/personalized) has announced the addition of the "The World Market For Personalized Medicine" report to their offering. This world market report includes important core medical product areas that will continue to have a powerful impact on current and future healthcare delivery. This business report examines key market segments such as targeted drugs and key personalized medicine diagnostics, including companion diagnostic IVDs, LDTs, diagnostic services and related tools or technologies. Many people already know about DNA, genes and the human genome. The science driving personalized medicine includes pharmacogenetics, pharmacoproteomics and pharmacometabalomix. Personalized medicine uses a targeted drug that depends on the patient information identified by a companion diagnostic (genetic biomarker test). The companion diagnostic identifies which patients would likely benefit from a particular therapy or those who might suffer from a ba
